ALFA Finder| Revenue growth | 28.2% YoY growth in FY26 to ₹39,308 Mn. |
|---|---|
| Margins | EBITDA margins compressed from 26.6% to 21.1%. |
| Demand visibility | Strong, evidenced by 25.4% growth in OP volumes. |
| Management confidence | High on regional leadership and clinical excellence strategy. |
Growth
FY26 Total Revenue grew 28.2% YoY; EBITDA grew 1.6% but margins compressed to 21.1% from 26.6% in FY25.
Outlook
Planned expansion to 8600+ beds including greenfield projects in Chennai (300 beds) and Kondapur II (800 beds).
Risks
PAT declined 41.7% YoY in FY26 due to expansion-related costs and initial losses in new clusters like Karnataka.
Earnings Call filed with NSE, NSE: KIMS. Summary written with AI assistance from the document.
Krishna Institute of Medical Sciences Ltd: key numbers
- Share price
- ₹722.00
- Market cap
- ₹30,324 Cr
- Revenue (annual)
- ₹3,905 Cr
- Net profit (annual)
- ₹241.4 Cr
- P/E (TTM)
- 142.8×Sector 54.5×
- Promoter holding
- 32.66%+0.16% QoQ
- FII holding
- 15.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Krishna Institute of Medical Sciences Ltd
All →Krishna Institute of Medical Sciences Earnings Call Transcript: Key Takeaways
KIMS delivered strong revenue growth led by Kondapur's rapid ramp-up, despite temporary margin compression from new oncology programs.
Krishna Institute of Medical Sciences Other Announcement
KIMS's CARE Ratings monitoring report shows ₹1,311.81 crore of the ₹1,476.45 crore QIP proceeds utilised till Q2 FY27. No deviation from the stated objects was reported.
Krishna Institute of Medical Sciences Management Change
KIMS re-appointed Dr. Abhinay Bollineni as Director & CEO, Dr. Bhaskara Rao Bollineni as CMD, and Ms. Dandamudi Anitha as Whole-time Director. Terms start in 2027.
- Execution
- 5 years
Krishna Institute of Medical Sciences Investor Presentation: Key Takeaways
Q2 FY27 total revenue Rs13,630 Mn (+41.3% YoY), EBITDA Rs2,789 Mn (20.5% margin), PAT Rs757 Mn (+5.1% YoY). Expansion via 700+ beds planned.
Krishna Institute of Medical Sciences Results Update
KIMS reported Q2 FY27 consolidated revenue of Rs 1,363 Crore, up 41.3% YoY, with PAT of Rs 76 Crore. EBITDA rose 34% YoY to Rs 279 Crore.
Krishna Institute of Medical Sciences Q2 FY27 Results: Net Profit ₹74.6 Cr, Up 3.6% YoY
Krishna Institute of Medical Sciences Ltd reported revenue from operations of ₹1,344 Cr (+39.9% YoY) and net profit of ₹74.6 Cr (+3.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹74.6 Cr · +3.6% YoY